Skip to Content
Biosimilars & Value Biologics

Same biologic outcome. Smarter cost.

The same biologic outcomes your patients rely on — with verified quality, dependable supply and smarter cost options.

39 Verified Biosimilars
20–50%Indicative Savings vs Originator
FDA / EMA / WHO Regulator-Approved
Adalimumab· Infliximab· Trastuzumab· Bevacizumab· Rituximab· Pegfilgrastim· Erythropoietin· Denosumab· Ustekinumab· Etanercept· Glargine· Eculizumab· Interchangeable-Where-Approved· Regulator-Approved· Cold-Chain Verified· Adalimumab· Infliximab· Trastuzumab· Bevacizumab· Rituximab· Pegfilgrastim· Erythropoietin· Denosumab· Ustekinumab· Etanercept· Glargine· Eculizumab· Interchangeable-Where-Approved· Regulator-Approved· Cold-Chain Verified·
The Biosimilar Case

Trusted equivalence, meaningful savings

Biosimilars are rigorously evaluated, regulator-approved biologics — equivalent in efficacy and safety to the originator, at a cost that lets your formulary and your patients go further.

Same clinical outcome Smarter cost
39
What We Supply

Value biologics across every class

39 verified biosimilars across the major biologic classes — immunology, oncology, supportive and specialty care, interchangeable where approved.

01Immunology
Adalimumab, infliximab, ustekinumab and etanercept
02Oncology biologics
Trastuzumab, bevacizumab, rituximab and pertuzumab
03Supportive care
Pegfilgrastim, filgrastim and erythropoietin
04Bone and specialty
Denosumab and ophthalmology biologics
05Insulin biologics
Glargine and aspart — interchangeable where approved
06Rare and specialty
Eculizumab, natalizumab and omalizumab
Making the Switch

We support the whole switch

Moving from originator to biosimilar is a clinical and operational decision — we support both, end to end.

1
Identify the switch
Reference biologic to verified biosimilar mapping
2
Assure quality
FDA/EMA/WHO-approved, registration-checked sourcing
3
Support the switch
Clinical and pharmacist substitution guidance
4
Sustain and save
Dependable, multi-source supply with smarter cost
Why
Why Partner With Us

Confidence in every switch

What an accountable biosimilars partner delivers for your institution.

Trusted equivalence
Rigorously evaluated, regulator-approved biosimilars — equivalent efficacy and safety to the originator.
Smarter cost options
Meaningful savings versus originator biologics that help your formulary and your patients.
Supply you can rely on
Two-to-three verified sources per molecule and cold-chain integrity protect against stock-outs.
Substitution made simple
Interchangeability guidance and switch support for pharmacy and clinical teams.
Reliability and Assurance

Quality you can switch to with confidence

Regulator-approved sourcing and resilient, cold-chain supply underpin every biosimilar we list.

FDA / EMA / WHO-PQ
Regulator-approved sourcing
20–50% range
Indicative savings vs originator
2–3
Verified sources per molecule
Validated 2–8 degrees C
Cold-chain integrity

Savings ranges and service levels shown are illustrative, agreed per institution in the supply agreement.

Our Promise

Widening access to the biologics that change lives

"Verified, interchangeable-where-approved biosimilars across immunology, oncology, supportive and specialty care."

39 verified biosimilars 20–50% savings One accountable route
39 Biosimilars · 6 Classes

Switch with confidence to value biologics

Talk to us about a biosimilars partnership that protects quality, supply and your formulary budget.